Avitia, an artificial intelligence (AI)-based diagnostics company, has announced its business launch with a $5m seed investment from PacBridge Capital Partners.
The diagnostics company has introduced its AI-powered platform for rapid & point-of-care cancer testing. The platform offers end-to-end testing to identify cancer mutations and treatments.
Laboratories and clinicians can access advanced molecular testing on-site, irrespective of their location.
According to Avitia, this technology helps healthcare teams provide faster, more accurate cancer insights and treatments at a lower cost.
The diagnostics company plans to use the funds to expand into new markets and enhance its platform’s capabilities.
Currently, its technology is used in Canada, the US, and Southeast Asia, with over 40,000 cancer mutation tests completed.
Avitia CEO and PacBridge partner James Lumsdaine said: “Avitia believes that all patients deserve access to advanced, cost-effective testing, regardless of geographic or economic constraints.
“Avitia will build on technology originally developed by Imagia Canexia Health, including an AI platform developed in Quebec in collaboration with Mila, the Quebec Artificial Intelligence Institute, to continue to deliver access to advanced cancer care to patients globally.”
Avitia’s technology provides advanced genomic testing with quick, actionable results for optimal patient outcomes.
Its modular platform enables on-site NGS testing at cancer centres, reducing turnaround times and costs compared to traditional send-out services.
Using AI-driven bioinformatics tailored to regional and patient-specific needs, the diagnostics company removes logistical barriers, allowing oncologists to test patients faster and make precise, personalised treatment decisions.
Avitia provides advanced NGS-molecular testing directly to laboratories through its AI/machine learning (ML) platform.
The company’s modular precision medicine technology equips cancer centres with advanced NGS capabilities and network-wide insights.
Its automated platform enables any lab to perform liquid biopsy assays on-site, reducing testing time and costs while enhancing patient outcomes.
